Lack of effect of gastric inhibitory polypeptide on hepatic and extrahepatic insulin action.
To assess the influence of enteric factors on insulin action, seven lean healthy subjects were studied under conditions of hyperinsulinemic euglycemic glucose clamp, double isotope administration, and enteral vs. parenteral glucose infusion. In random order, glucose and mannitol radiolabeled with [2-3H]glucose were infused intraduodenally for 4 h while the systemic rate of glucose turnover was assessed by [6-14C]glucose. During the final hour of the study, plasma glucose, insulin, C-peptide, glucagon, cholecystokinin, and neurotensin were similar under both experimental conditions. Despite an increase in gastric inhibitory polypeptide concentration during combined enteral and iv glucose infusion to levels that mimicked meal ingestion, total glucose infusion rate, insulin-induced stimulation of glucose uptake, and insulin-induced suppression of hepatic glucose release were comparable to those observed during iv glucose administration. These data indicate that under conditions of modest hyperinsulinemia and euglycemia, gastric inhibitory polypeptide did not influence hepatic or extrahepatic insulin action.
Service
F J
FJ
Endocrine Research Unit, Mayo Medical School, Rochester, Minnesota 55905.
Heiling
V J
VJ
Go
V L
VL
Rizza
R A
RA
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000378:metabolism; D002766:Cholecystokinin / Q000378:metabolism / Q000502:physiology; D004386:Duodenum / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism / Q000502:physiology*; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000378:metabolism; D006946:Hyperinsulinism / Q000378:metabolism; D007263:Infusions, Parenteral; D007328:Insulin / Q000008:administration & dosage / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008353:Mannitol / Q000008:administration & dosage; D013154:Spleen / Q000187:drug effects* / Q000378:metabolism
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D008353:Mannitol; D005749:Gastric Inhibitory Polypeptide; D002766:Cholecystokinin; D005947:Glucose